ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Search by Abstract Number Results

  • Abstract Number: 0086 • ACR Convergence 2024

    Evaluating the Efficacyof B Cell Targeting Drug Candidates Using a Humanized BAFF Transgenic SLE Mouse Model

    Juan Liang, Shuxin Xu, Qiuping Xu and Yuxi Zhang, GemPharmatech, San Diego

    Background/Purpose: B-cell-activating factor (BAFF) plays a critical role in B cell survival, and its elevated expression can contribute to the presence of autoreactive B cells,…
  • Abstract Number: 0086 • ACR Convergence 2023

    Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

    Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA

    Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
  • Abstract Number: 0086 • ACR Convergence 2022

    Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis

    Monica Crespo Bosque1, Pablo Weilg Espejo2 and Candace Feldman3, 1Boston University, Boston, MA, 2Boston Medical Center, Chelsea, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Latinx patients, a heterogenous population with a range of experiences including migration, language, and race, experience a disproportionate burden of adverse outcomes from systemic…
  • Abstract Number: 0086 • ACR Convergence 2021

    SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review

    Richard Conway1, Alyssa Grimshaw2, Maximilian Konig3, Michael Putman4, Ali Duarte-Garcia5, Candice Low6, Shangyi Jin7, Diego Cabrera8, Yu Pei Eugenia Chock9, Berk Degirmenci10, Eimear Duff11, Bugra Egeli12, Elizabeth Graef13, Akash Gupta14, Patricia Harkins15, Bimba Franziska Hoyer16, Aruni Jayatilleke17, Christopher Kasia18, Aneka Khilnani19, Adam Kilian20, Alfred Kim21, Chung Mun Alice Lin22, Laurie Proulx23, Sebastian Sattui24, Namrata Singh25, Jeffrey Sparks26, Herman Tam27, Leslie Yingzhijie Tseng2, Manuel Ugarte-Gil28, Natasha Ung29, Leanna Wise30, Ziyi Yang31, Kristen Young32, Jean Liew33, Rebecca Grainger34, Zachary Wallace35 and Evelyn Hsieh2, 1St. James's University Hospital, Dublin, Ireland, 2Yale School of Medicine, New Haven, CT, 3The Johns Hopkins University School of Medicine, Baltimore, MD, 4Medical College of Wisconsin, Brookfield, WI, 5Mayo Clinic, Rochester, MN, 6St. Vincent's University Hospital, Dublin, Ireland, 7Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), 8Yale School of Medicine, Lima, Peru, 9Yale School of Medicine, Greenwich, CT, 10St. Elizabeth's Medical Center, Boston, MA, 11St. James's Hospital, Dublin, Ireland, 12Boston Children's Hospital, Boston, MA, 13Emerson Hospital, Concord, MA, 14Department of Medicine, Yale University School of Medicine, New Haven, CT, 15St James hospital, Dublin, Ireland, 16Universittsklinikum Schleswig-Holstein, Kiel, Germany, 17Temple University, Philadelphia, PA, 18The Medical College of Wisconsin, Maywood, IL, 19George Washington University School of Medicine and Health Sciences, Washington, DC, 20George Washington University, Melbourne, FL, 21Washington University School of Medicine, St. Louis, MO, 22Newcastle University, Newcastle, United Kingdom, 23Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, 24Hospital for Special Surgery, New York, NY, 25University of Washington, Bellevue, WA, 26Brigham and Women's Hospital, Boston, MA, 27Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, 28Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 29New South Wales Health, Sydney, Australia, 30LAC+USC/Keck Medicine of USC, Pasadena, CA, 31Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing 100730, China, Beijing, China (People's Republic), 32University of Texas Southwestern Medical Center, Dallas, TX, 33Boston University, Boston, MA, 34University of Otago, Wellington, New Zealand, 35Massachusetts General Hospital, Newton, MA

    Background/Purpose: The relative risk of COVID-19 among patients with rheumatic and musculoskeletal disease (RMD) and the comparative severity of COVID-19 infection in RMD remain uncertain.…
  • Abstract Number: 0086 • ACR Convergence 2020

    Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers

    Bina Kassamali1, Anastasiya Muntyanu2, Ruth Ann Vleugels3 and Avery LaChance3, 1Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 2McGill University, Montreal, QC, Canada, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by induration progressing proximally along the upper and lower extremities. Given the…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology